Yantai Zhenghai Bio-Tech (300653.SZ): Buyback completed, with a total expenditure of 49.9204 million yuan to repurchase 2.3601 million shares.

Gelonghui reported on December 20 that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of the date of the announcement, the share buyback plan has been fully implemented. To date, the company has repurchased 2.36005 million shares of the company through a dedicated securities account via concentrated bidding, accounting for 1.31% of the company’s total share capital. The highest Fill Price was 24.83 yuan/share, and the lowest Fill Price was 17.90 yuan/share, with a total amount paid of 49.9204 million yuan (excluding transaction costs).

Gelonghui FinanceDec 20 15:54

Yantai Zhenghai Bio-Tech (300653.SZ): The company currently has no AI pharmaceutical Business.

On December 17, Glonghui reported that Yantai Zhenghai Bio-Tech (300653.SZ) stated on the investor interaction platform that the company currently has no AI pharmaceutical Business.

Gelonghui FinanceDec 17 15:36

Express News | yantai zhenghai bio-tech: The company has received the "Acceptance Notice" for the medical instruments registration application.

BreakingsNov 18 16:30

yantai zhenghai bio-tech (300653.SZ): has repurchased 0.927% of the shares.

On November 4th, GeLongHui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of October 31, 2024, the company repurchased 1,668,600 shares through a special stock repurchase account for the centralized auction trading method, accounting for 0.9270% of the total share capital. The highest fill price was 24.83 yuan/share, the lowest fill price was 17.90 yuan/share, and the total amount paid was 34.2793 million yuan (excluding transaction costs).

Gelonghui FinanceNov 4 16:36

Zhenghai Biotech: Report for the third quarter of 2024

SZSIOct 23 00:00 · Announcements

Yantai Zhenghai Bio-Tech (300653.SZ): Intends to cancel the wholly-owned subsidiary Suzhou Zhenghai Biotechnology Co., Ltd.

October 22, Bio-tech (300653.SZ) announced that, in order to optimize the allocation of company resources, improve operation management efficiency, and reduce management costs, the company has decided to cancel its wholly-owned subsidiary Suzhou Zhenghai Bio-tech Technology Co., Ltd. The cancellation of this subsidiary will not have any adverse impact on the company's future business development and overall profitability. After this cancellation is completed, Suzhou Zhenghai Bio-tech Technology Co., Ltd. will no longer be included in the company's consolidated financial statements.

Gelonghui FinanceOct 22 17:11